ArticleSmall (Weinheim an der Bergstrasse, Germany)2008
Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH.
Article in Small (Weinheim an der Bergstrasse, Germany), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 310 citations in OpenAlex.
- Upconversion Nanoparticle-Covalent Organic Framework Core-shell Particles as Therapeutic Microrobots Trackable With Optoacoustic Imaging.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Combination of mannoside and phenylboronic acid polycaprolactone polymers for doxorubicin-encapsulated polymersome nanomedicine targeting MDA-MB-231 cancer cells.Drug delivery and translational research · 2025Article
- Synthesis andResearch in pharmaceutical sciences · 2025Article
- Intracellular Delivery of Therapeutic Protein via Ultrathin Layered Double Hydroxide Nanosheets.Pharmaceutics · 2024Article
- Tumor Microenvironment-Based Stimuli-Responsive Nanoparticles for Controlled Release of Drugs in Cancer Therapy.Pharmaceutics · 2022Review
- Endosomal Escape of Bioactives Deployed via Nanocarriers: Insights Into the Design of Polymeric Micelles.Pharmaceutical research · 2022Review
- Strategy for Cytoplasmic Delivery Using Inorganic Particles.Pharmaceutical research · 2022Review
- Encapsulation, Release, and Cytotoxicity of Doxorubicin Loaded in Liposomes, Micelles, and Metal-Organic Frameworks: A Review.Pharmaceutics · 2022Review
- A spotlight on alkaloid nanoformulations for the treatment of lung cancer.Frontiers in oncology · 2022Review
- Strategies for the Development of pH-Responsive Synthetic Polypeptides and Polymer-Peptide Hybrids: Recent Advancements.Polymers · 2021Review
- Micelles Based on Lysine, Histidine, or Arginine: Designing Structures for Enhanced Drug Delivery.Frontiers in bioengineering and biotechnology · 2021Review
- An On-Demand pH-Sensitive Nanocluster for Cancer Treatment by Combining Photothermal Therapy and Chemotherapy.Pharmaceutics · 2020Article
- Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.Cancer science · 2020Article
- Review
- Increasing Doxorubicin Loading in Lipid-Shelled Perfluoropropane NanobubblesFrontiers in pharmacology · 2020Article
- Subcellular Performance of Nanoparticles in Cancer Therapy.International journal of nanomedicine · 2020Review
- Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy.Cancers · 2019Review
- Micelle-Forming Block Copolymers Tailored for Inhibition of P-gp-Mediated Multidrug Resistance: Structure to Activity Relationship.Pharmaceutics · 2019Article
- Review
- A DOX-loaded polymer micelle for effectively inhibiting cancer cells.RSC advances · 2018Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
An optimized, pH-sensitive mixed-micelle system conjugated with folic acid is prepared in order to challenge multidrug resistance (MDR) in cancers. The micelles are composed of poly(histidine (His)-co-phenylalanine (Phe))-b-poly(ethylene glycol) (PEG) and poly(L-lactic acid) (PLLA)-b-PEG-folate. Core-forming, pH-sensitive hydrophobic blocks of poly(His-co-Phe) of varying composition are synthesized. The pH sensitivity of the micelles is controlled by the copolymer composition and is fine tuned to early endosomal pH by blending PLLA(3K)-b-PEG(2K)-folate in the presence of a basic anticancer drug, doxorubicin (DOX). In vitro tests are conducted against both wild-type (A2780) and DOX-resistant ovarian carcinoma cell lines. A mixed-micelle system composed of poly(His-co-Phe (16 mole%))-b-PEG (80 wt%) and PLLA-b-PEG-folate (20 wt%) is selected to target early endosomal pH. DOX-loaded micelles effectively kill both wild-type sensitive (A2780) and DOX-resistant ovarian MDR cancer-cell lines (A2780/DOX(R)) through an instantaneous high dose of DOX in the cytosol, which results from active internalization, accelerated DOX release triggered by endosomal pH, and an endosomal membrance disruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.